It may be that the views of GPs regarding the value of the PSA test will be affected by evidence from two large-scale randomised screening trials being conducted in Europe and the USA, aiming to assess whether PSA screening reduces prostate cancer mortality [15]. The gene discussed is KLK3; the disease is prostate carcinoma.